Stock Analysis on Net
Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check

Short-term Activity Ratios (Summary)

Vertex Pharmaceuticals Inc., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Turnover Ratios
Inventory turnover
Receivables turnover
Payables turnover
Working capital turnover
Average No. Days
Average inventory processing period
Add: Average receivable collection period
Operating cycle
Less: Average payables payment period
Cash conversion cycle

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The analyzed period reveals a significant expansion in the operational cycle, driven primarily by a marked decline in inventory efficiency. While receivables management remained stable, the overall cash conversion cycle increased substantially, indicating a longer duration between the outlay of cash for inventory and the receipt of cash from sales.

Inventory Management Efficiency
A consistent downward trend is observed in inventory turnover, which declined from 2.83 in March 2022 to 1.00 by June 2026. Correspondingly, the average inventory processing period grew from 129 days to 365 days. This trajectory suggests a significant slowdown in inventory movement and a substantial increase in the amount of capital tied up in stock.
Receivables and Payables Dynamics
Receivables turnover remained relatively constant, fluctuating within a narrow range between 5.68 and 6.85. The average receivable collection period showed minimal variance, consistently hovering around 60 days, which indicates a stable and predictable credit collection process. Conversely, payables turnover exhibited higher volatility, generally trending lower than initial levels. The average payables payment period expanded from 66 days to 89 days, though it experienced intermittent fluctuations, such as a notable dip to 44 days in September 2022.
Working Capital and Cash Conversion
Working capital turnover demonstrated an upward trajectory, particularly from March 2024 onwards, rising from 0.97 to 1.46. This suggests an improvement in the efficiency of using working capital to generate revenue. However, this improvement was offset by the lengthening operating cycle, which grew from 188 days to 427 days. Consequently, the cash conversion cycle expanded from 122 days in March 2022 to 338 days by June 2026, reflecting a systemic increase in the time required to convert resource inputs into cash flows.

Turnover Ratios


Average No. Days


Inventory Turnover

Vertex Pharmaceuticals Inc., inventory turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Cost of sales
Inventories
Short-term Activity Ratio
Inventory turnover1
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Inventory turnover = (Cost of salesQ2 2026 + Cost of salesQ1 2026 + Cost of salesQ4 2025 + Cost of salesQ3 2025) ÷ Inventories
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


An analysis of the operating activity ratios reveals a consistent and significant decline in inventory efficiency over the period from March 31, 2022, to June 30, 2026. While the cost of sales has increased, this growth has been vastly eclipsed by the rate of inventory accumulation, leading to a steady deterioration of the inventory turnover ratio.

Cost of Sales Trends
The cost of sales exhibits a general upward trajectory, rising from 245,800 thousand US$ in March 2022 to 489,200 thousand US$ by June 2026. Although there are periodic quarterly fluctuations—such as the dip observed in March 2023 and March 2025—the long-term trend indicates a substantial increase in the volume of goods sold or the cost associated with production.
Inventory Accumulation
Inventories have grown aggressively and consistently throughout the analyzed period. Starting at 338,900 thousand US$ in March 2022, the balance escalated to 1,765,100 thousand US$ by June 2026. This represents a more than five-fold increase in inventory holdings, suggesting a strategic shift toward higher stockpiling or a decrease in the speed of product distribution.
Inventory Turnover Performance
The inventory turnover ratio shows a continuous downward trend, falling from a high of 2.83 in March 2022 to 1.00 in June 2026. A critical threshold was crossed in June 2023 when the ratio fell below 2.00, and it further declined below 1.00 between September and December 2025 before stabilizing around 1.00 in the final quarter. This trend indicates that the company is taking significantly longer to turn over its inventory, which may point to increased carrying costs or a misalignment between production levels and market demand.

The divergence between the moderate growth in the cost of sales and the rapid expansion of inventory levels confirms a diminishing efficiency in inventory management. The reduction in the turnover ratio suggests that capital is increasingly tied up in non-liquid assets, impacting the overall short-term operational agility of the organization.


Receivables Turnover

Vertex Pharmaceuticals Inc., receivables turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Revenues
Accounts receivable, net
Short-term Activity Ratio
Receivables turnover1
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Receivables turnover = (RevenuesQ2 2026 + RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025) ÷ Accounts receivable, net
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


An analysis of the operating activity from March 31, 2022, to June 30, 2026, reveals a consistent expansion in both top-line revenue and the corresponding accounts receivable balance, while the efficiency of collections remained relatively stable.

Revenue and Receivables Growth
Revenues exhibited a steady upward trajectory, increasing from 2,097,500 thousand USD in March 2022 to 3,333,900 thousand USD by June 2026. Parallel to this growth, net accounts receivable rose from 1,292,800 thousand USD to 2,134,300 thousand USD over the same period. This proportional increase suggests that the growth in credit sales is aligned with the overall expansion of business operations.
Receivables Turnover Stability
The receivables turnover ratio remained remarkably consistent, generally fluctuating within a narrow band between 5.68 and 6.85. This stability indicates that the company has maintained a disciplined credit policy and a consistent collection cycle despite significant increases in the volume of sales.
Volatility and Peak Performance
Minor fluctuations in turnover efficiency are observable. A notable dip occurred on March 31, 2024, where the ratio reached its lowest point of 5.68, followed by a significant peak of 6.85 on December 31, 2024. The most recent data point as of June 30, 2026, shows a ratio of 5.90, returning the metric to its historical average range.
Operational Efficiency Insight
The lack of a sustained downward trend in the turnover ratio, despite the growth in receivables, suggests that the company is not experiencing a deterioration in the quality of its receivables or a slowdown in payment collection from customers.

Payables Turnover

Vertex Pharmaceuticals Inc., payables turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Cost of sales
Accounts payable
Short-term Activity Ratio
Payables turnover1
Benchmarks
Payables Turnover, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Payables turnover = (Cost of salesQ2 2026 + Cost of salesQ1 2026 + Cost of salesQ4 2025 + Cost of salesQ3 2025) ÷ Accounts payable
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a transition from significant volatility in payables management to a period of relative stabilization over the observed timeframe.

Payables Turnover Trends
The payables turnover ratio exhibited substantial fluctuations during 2022, reaching a peak of 8.23 in September 2022. This spike coincided with a marked decrease in accounts payable. Following this period, the ratio entered a phase of stabilization, generally oscillating between 3.13 and 4.27 from March 2023 through June 2026. This suggests a move toward a more predictable and standardized payment cycle.
Correlation Between Costs and Obligations
A consistent upward trajectory in the cost of sales is observed, increasing from 245.8 million USD in March 2022 to 489.2 million USD by June 2026. Parallel to this growth, accounts payable increased from 173.6 million USD to a peak of 489.3 million USD in March 2026. The simultaneous growth of both metrics indicates that the scaling of operational costs has been supported by a corresponding increase in supplier credit.
Credit Management and Operational Efficiency
The convergence of the turnover ratio into a tighter range since early 2023 indicates a disciplined approach to credit management. Despite the cost of sales nearly doubling over the period, the ability to maintain the turnover ratio between 3.1 and 4.3 suggests that the company has successfully scaled its procurement processes without significantly altering its payment terms or liquidity profile regarding supplier obligations.

Working Capital Turnover

Vertex Pharmaceuticals Inc., working capital turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Current assets
Less: Current liabilities
Working capital
 
Revenues
Short-term Activity Ratio
Working capital turnover1
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Working capital turnover = (RevenuesQ2 2026 + RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025) ÷ Working capital
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The financial data reveals a distinct shift in operational efficiency and working capital management between the 2022-2023 period and the 2024-2026 period. While revenues exhibited a consistent upward trajectory, the working capital turnover ratio experienced significant volatility, driven primarily by a substantial contraction in working capital during the first half of 2024.

Revenue Growth Trends
A steady increase in quarterly revenues is observed, rising from 2,097,500 thousand USD in March 2022 to 3,333,900 thousand USD by June 2026. This consistent growth indicates a sustained expansion in the company's top-line performance over the analyzed timeframe.
Working Capital Fluctuations
Working capital initially grew from 8,181,100 thousand USD in March 2022 to a peak of 11,096,400 thousand USD in September 2023. However, a sharp decline occurred between March 2024 and June 2024, where working capital dropped from 9,492,800 thousand USD to 5,394,400 thousand USD. Following this trough, a gradual recovery is noted, with the figure climbing back to 8,605,800 thousand USD by June 2026.
Working Capital Turnover Dynamics
The turnover ratio remained relatively low and stable between 0.85 and 0.97 from March 2022 through December 2023, suggesting that revenue growth was being outpaced by the accumulation of working capital. A pivot occurred in June 2024, where the ratio spiked to 1.92, coinciding with the sharp reduction in working capital. This indicates a period of significantly higher operational efficiency in utilizing current assets and liabilities to generate sales.
Efficiency Normalization
From June 2024 to June 2026, the turnover ratio exhibited a gradual downward trend, moving from 1.92 to 1.46. This decline suggests that while the company maintained a higher efficiency level than in the 2022-2023 period, the subsequent increase in working capital began to grow at a rate that offset the gains in revenue growth.

Average Inventory Processing Period

Vertex Pharmaceuticals Inc., average inventory processing period calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Inventory turnover
Short-term Activity Ratio (no. days)
Average inventory processing period1
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The operational activity analysis reveals a sustained and significant deterioration in inventory efficiency over the period from March 2022 to June 2026.

Inventory Turnover Dynamics
A continuous downward trend is observed in the inventory turnover ratio, which declined from 2.83 in March 2022 to 1.00 by June 2026. This steady reduction indicates a slowing rate of inventory liquidation and a decrease in the frequency with which inventory is replaced throughout the analyzed timeframe.
Average Inventory Processing Period
Correspondingly, the average inventory processing period exhibits a substantial upward trajectory. The duration required to process inventory increased from 129 days in March 2022 to 365 days in June 2026. This expansion represents a nearly threefold increase in the time inventory remains on the balance sheet before conversion into sales.
Correlation and Temporal Patterns
A strict inverse relationship is evident between the turnover ratio and the processing period. The growth in the processing period was relatively moderate throughout 2022 but accelerated significantly starting in 2023. The most pronounced expansion occurred between March 2024 and March 2026, during which the period climbed from 222 days to a peak of 384 days, before settling at 365 days in the final reporting period. This pattern suggests a fundamental shift in inventory management strategy or a significant increase in the accumulation of slow-moving stock.

Average Receivable Collection Period

Vertex Pharmaceuticals Inc., average receivable collection period calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Receivables turnover
Short-term Activity Ratio (no. days)
Average receivable collection period1
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a consistent and stable pattern in the management of receivables from March 2022 through June 2026. The efficiency of credit collection remains largely steady, with minimal volatility in the time required to convert receivables into cash.

Average Receivable Collection Period
The collection period typically fluctuates within a narrow range of 58 to 62 days. A peak of 64 days was observed on March 31, 2024, representing the least efficient period of collection. Conversely, the most significant improvement in collection efficiency occurred on December 31, 2024, when the period decreased to 53 days. Following this low, the collection cycle returned to its historical baseline, ending at 62 days by June 30, 2026.
Receivables Turnover
The turnover ratio maintains a stable trend, generally hovering around 6.0. The highest turnover rate of 6.85 was recorded on December 31, 2024, which aligns with the shortest collection period. The lowest turnover rate of 5.68 occurred on March 31, 2024, coinciding with the longest collection period. These fluctuations indicate a strong inverse correlation between the turnover ratio and the collection period.
Operational Consistency
The stability of these metrics suggests a standardized approach to credit terms and collection processes. The absence of long-term upward or downward trends in the collection period indicates that the company has maintained a consistent credit policy over the analyzed timeframe, with only minor quarterly variances.

Operating Cycle

Vertex Pharmaceuticals Inc., operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Average inventory processing period
Average receivable collection period
Short-term Activity Ratio
Operating cycle1
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =

2 Click competitor name to see calculations.


The operating cycle exhibits a sustained and significant expansion over the analyzed period, growing from 188 days in March 2022 to a peak of 444 days in March 2026, before settling at 427 days by June 2026. This overall increase indicates a substantial slowing in the time required to convert raw materials and inventories into cash.

Average Inventory Processing Period
A pronounced upward trend is observed in the inventory processing period, which rose from 129 days in March 2022 to 365 days by June 2026. The growth was relatively steady through 2022 but accelerated significantly starting in 2023. A notable escalation occurred between December 2023 (214 days) and March 2025 (320 days), with the period reaching its maximum of 384 days in March 2026. This trend suggests a systematic increase in inventory holding times or a shift in production and distribution strategies.
Average Receivable Collection Period
In contrast to inventory metrics, the receivable collection period remained remarkably stable throughout the entire timeframe. Values fluctuated within a narrow range, starting at 59 days in March 2022 and ending at 62 days in June 2026. The shortest collection period was recorded in December 2023 at 53 days, while the peak was 64 days in March 2024. This stability indicates that the efficiency of credit and collection processes has been maintained despite changes in other operating activities.
Operating Cycle Analysis
The extension of the total operating cycle is almost exclusively driven by the increase in the inventory processing period. Because the receivable collection period remained flat, the rise in the operating cycle from 188 to 427 days reflects a direct correlation with the lengthening time to move inventory. The most aggressive expansion of the cycle occurred between September 2024 (327 days) and March 2026 (444 days), suggesting an increasing amount of working capital is tied up in the production and storage phases of the business model.

Average Payables Payment Period

Vertex Pharmaceuticals Inc., average payables payment period calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Payables turnover
Short-term Activity Ratio (no. days)
Average payables payment period1
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


An analysis of the operating activity ratios reveals a significant shift in the management of accounts payable between 2022 and 2026. The company transitioned from a relatively aggressive payment schedule to a more extended credit cycle, effectively increasing the duration taken to settle obligations with suppliers.

Payables Turnover Trends
The payables turnover ratio exhibited considerable volatility during 2022, reaching a peak of 8.23 in September before declining sharply to 3.55 by December of that year. From 2023 through mid-2026, the ratio stabilized within a narrower range, generally fluctuating between 3.13 and 4.27. This downward shift from the initial higher turnover rates indicates a reduction in the frequency with which accounts payable were cleared during the observed period.
Average Payables Payment Period
The average period for settling payables underwent a substantial expansion. After reaching a minimum of 44 days in September 2022, the payment period surged to 103 days by December 2022 and peaked at 117 days in September 2023. While a temporary contraction to 85 days occurred in June 2024, the payment period remained consistently elevated, typically oscillating between 95 and 107 days through March 2026, before retreating to 89 days in June 2026.
Operational Liquidity Implications
The observed patterns suggest a strategic shift toward the preservation of cash flow by extending the payment window for suppliers. The transition from a payment cycle that was frequently under 75 days in early 2022 to a cycle that often exceeded 100 days indicates an optimization of the cash conversion cycle. This expansion enhances short-term liquidity by delaying cash outflows, thereby increasing the organization's reliance on supplier-provided financing to fund operations.

Cash Conversion Cycle

Vertex Pharmaceuticals Inc., cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Average inventory processing period
Average receivable collection period
Average payables payment period
Short-term Activity Ratio
Cash conversion cycle1
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + =

2 Click competitor name to see calculations.


The cash conversion cycle has undergone a significant expansion over the analyzed period, increasing from 122 days in March 2022 to 338 days by June 2026. This trend indicates a substantial slowdown in the speed at which working capital is converted back into cash, primarily driven by a consistent and aggressive increase in the time required to process inventory.

Average Inventory Processing Period
A pronounced upward trend is observed in inventory processing, which rose from 129 days in March 2022 to a peak of 384 days in March 2026, before slightly moderating to 365 days in June 2026. This metric represents the most significant driver of the overall cash conversion cycle, showing a nearly threefold increase over the period. The progression was steady, with a notable acceleration beginning in 2023 and continuing through 2025.
Average Receivable Collection Period
The collection of receivables remained relatively stable throughout the analyzed timeframe. Values fluctuated within a narrow range, primarily between 53 and 64 days. The lack of a significant upward or downward trend suggests that credit policies and collection efficiency remained consistent, contributing minimally to the changes in the overall cash conversion cycle.
Average Payables Payment Period
The payables payment period exhibited considerable volatility in the early stages, dropping to 44 days in September 2022 before climbing to a peak of 117 days in September 2023. In the subsequent periods, the payment period stabilized, generally fluctuating between 85 and 106 days. While the company extended its payment terms compared to the start of 2022, this extension was insufficient to offset the increase in inventory holding times.
Cash Conversion Cycle Synthesis
The overall cash conversion cycle shifted from 122 days to 338 days, reflecting a marked decrease in operational liquidity efficiency. Because the receivable collection period remained flat and the payables payment period stabilized, the expansion of the cycle is almost entirely attributable to the lengthening inventory processing period. This suggests a significant increase in the amount of capital tied up in inventory over the recorded quarters.